Verition Fund Management
ASBP

Verition Fund Management’s Aspire Biopharma ASBP Stock Holding History

Verition Fund Management’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-81
Closed -$12.8K – 3766
2025
Q4 		$12.8K Buy
+81
New +$20.3K ﹤0.01% 3437
2023
Q2 		– Sell
-333
Closed -$4.19M – 2607
2023
Q1 		$4.19M Sell
333
-244
-42% -$3.05M 0.06% 432
2022
Q4 		$7.13M Sell
577
-6
-1% -$73.5K 0.11% 218
2022
Q3 		$7.1M Sell
583
-167
-22% -$2.02M 0.08% 288
2022
Q2 		$8.98M Buy
+750
New +$8.98M 0.18% 117

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Verition Fund Management's ASBP Position: Q1 2026 in Review

Verition Fund Management sold out of Aspire Biopharma (ASBP) in Q1 2026, closing a stake of 81 shares — an estimated $12.8K sold.

Verition Fund Management first reported a position in ASBP in Q2 2022 and held it in 5 quarters. The position peaked at $8.98M in Q2 2022. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

  • Verition Fund Management reported no remaining Aspire Biopharma position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 81 Aspire Biopharma shares in Q1 2026, an estimated $12.8K.
  • Verition Fund Management first reported a position in Aspire Biopharma in Q2 2022 and held it in 5 quarters.
  • Verition Fund Management's Aspire Biopharma position peaked at $8.98M in Q2 2022.
  • 12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.